Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
about
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress DisordersCurrent and potential pharmacological treatments for obsessive-compulsive disorderSelective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)Genetics of obsessive-compulsive disorderGlutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.Sertraline in the treatment of anxiety disorders.A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.Clinical treatment of obsessive compulsive disorderWhich antidepressant?Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.Epigenetic abnormalities associated with a chromosome 18(q21-q22) inversion and a Gilles de la Tourette syndrome phenotype.Obsessive compulsive disorder: serotonin and beyond.Diagnosis and treatment of pathologic gambling.Open-label study of duloxetine for the treatment of obsessive-compulsive disorder.Obsessive-compulsive disorder and its related disorders: a reappraisal of obsessive-compulsive spectrum concepts.A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation.Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.Antipsychotic treatment in obsessive-compulsive disorder: a literature review.Minority participation in randomized controlled trials for obsessive-compulsive disorder.Fluvoxamine in the treatment of anxiety disorders.Determination of fluvoxamine concentration in plasma by reversed-phase liquid chromatography.An update on the pharmacological treatment of obsessive-compulsive disorder.Obsessive-compulsive disorder. Characteristic features, pharmacologic management.Where does obsessive-compulsive disorder belong in DSM-V?Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis.Experimental therapeutics for refractory obsessive-compulsive disorder: translational approaches and new somatic developments.Serotonin selectivity for obsessive compulsive and panic disordersLong-term outcome in adults with obsessive-compulsive disorder.Treatment strategies for obsessive-compulsive disorder.Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.BAP/SKB Young Psychopharmacologist Award Towards a neuroendocrinology of obsessive-compulsive disorder.The nature, assessment, and treatment of obsessive-compulsive disorder.Serotonin in obsessions, compulsions, and the control of aggressive impulses.An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder.Pharmacological treatment of obsessive-compulsive disorderAre 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature.A Proposed Algorithm for Improved Recognition and Treatment of the Depression/Anxiety Spectrum in Primary Care.Are the eating disorders related to obsessive compulsive disorder?Contemporary approaches to pharmacotherapy in Tourette's syndrome and obsessive-compulsive disorder.
P2860
Q22305681-2B030D6A-F1DD-456B-87BB-A4BDABF4139BQ22306025-21795711-E021-493C-BACD-25DC6DD2185FQ24242402-929144B0-3D9E-4636-9D3F-861E786A9E12Q24645479-BEED3C49-970B-44CD-91F9-07DB230D2FF4Q31032734-05F44385-8BD9-46CD-9E10-9447AAB4629EQ33914087-85400FB9-8E10-43AE-8E4A-5E96C9361B6BQ33994634-E4934873-0CB6-42C8-86A1-B39A0CA8F58EQ34359796-BB02298C-042A-4012-9953-61A06F8D6DBBQ34369018-27C6EEF2-9670-47DF-93A0-E44EFE193417Q34678136-C8B6A086-1413-4D51-B9F7-888902CC040DQ34865036-7B561651-F83C-4CB9-B50E-6E6942DC0342Q34959586-989678DA-95E2-434F-9796-5D935FA35D6DQ35073812-D0712F97-1519-4CD8-B2B5-A142F536433BQ35103438-DFA0C6FF-9BE9-4315-BEA4-0C5CF8739485Q35203670-CBA3FE26-F4F8-4A2E-A2F9-F2FF163F6E15Q35237204-37CFF6CF-7F90-4456-9DE1-33BA78FF2AF1Q35936259-7622E9A2-A94E-45CC-B787-DEB8E4443E69Q36029739-1E53ABFD-F388-4681-9B35-FC8838C32522Q36110049-2153892A-F53E-4DEB-A196-A0DFCD31684BQ36200991-52F56035-539D-4712-B53A-04EDCA696620Q36713425-1725C2C6-18A0-4304-8D9A-EAFC2D5BBA12Q36719437-719B3897-091F-42FF-93C0-8515174C0565Q36765772-2D8D6166-84AA-4078-B437-8027DC1587B8Q36771320-E7D203D0-2389-459B-9A5B-FE3226B9A5EEQ37138385-4CC57C77-6372-4660-8D4E-A377B559F3B5Q37140673-AE1052EA-C787-4801-926A-D6AA6C51A0E8Q37244055-D03020C1-5962-4A75-9D81-9EBB3A069738Q37423109-55F28AA9-B27B-459E-9D3A-3474083F088BQ37598903-7EAE5C67-EAF5-40C1-9728-461DCF14BA3EQ37681560-99BDBD5E-3CCB-4868-876A-28AD58CABE4BQ37682681-DC5F0285-1C6C-4959-B491-54B32E0CDDF8Q37980721-EAEBB5A7-69FA-48B6-A7AC-B418A95086FFQ37982217-2E5BDCBE-3C21-47FB-AE9F-F1DA1D8EC8F5Q38004480-D23A263E-9EC6-4E03-BB5A-F94C877E0117Q38207094-F79B9764-B486-4F2D-ADF2-E74538537E40Q38242548-CEB2490B-6CC7-469D-9C24-650E0BD77905Q38353212-48A0DB76-719A-467F-81D2-A7258E724C1CQ39853665-E957A771-A4F0-43EA-942A-9C6DE8043105Q40797850-BBE33F1A-7955-41BA-9C2C-C37B983E2F3DQ41025805-9123E788-8B12-4A49-A459-0A81EB9AB8B4
P2860
Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Efficacy of fluvoxamine in obs ...... blind comparison with placebo.
@en
type
label
Efficacy of fluvoxamine in obs ...... blind comparison with placebo.
@en
prefLabel
Efficacy of fluvoxamine in obs ...... blind comparison with placebo.
@en
P2093
P1433
P1476
Efficacy of fluvoxamine in obs ...... blind comparison with placebo.
@en
P2093
Charney DS
Delgado PL
Goodman WK
Heninger GR
Rasmussen SA
P356
10.1001/ARCHPSYC.1989.01810010038006
P407
P577
1989-01-01T00:00:00Z